Zimmer Biomet: Q3 Earnings Insights

Shares of Zimmer Biomet Holdings ZBH were unchanged after the company reported Q3 results.

Quarterly Results

Earnings per share increased 2.26% year over year to $1.81, which beat the estimate of $1.07.

Revenue of $1,929,000,000 rose by 1.96% year over year, which beat the estimate of $1,710,000,000.

Guidance

Zimmer Biomet Holdings hasn't issued any earnings guidance for the time being.

Zimmer Biomet Holdings hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: Nov 06, 2020

Time: 08:30 AM

ET Webcast URL: https://78449.choruscall.com/dataconf/productusers/zbh/mediaframe/41142/indexr.html

Price Action

Company's 52-week high was at $161.11

Company's 52-week low was at $74.37

Price action over last quarter: Up 4.28%

Company Overview

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 60% of total revenue is derived from sales of large joints, another 22% comes from extremities and trauma; the remaining portion is primarily related to spine and dental products.